Overview

Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

Status:
Active, not recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, parallel-group study to evaluate the safety and efficacy of ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
Phase:
Phase 2
Details
Lead Sponsor:
Suven Life Sciences Limited